Paratesticular adenocarcinoma
ORPHA:363478DiseaseAdult
Эпидемиология14
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Lifetime Prevalence | <1 / 1 000 000 | 0.01 | Europe | Value and class |
| Point prevalence | <1 / 1 000 000 | — | Europe | Class only |
| Annual incidence | <1 / 1 000 000 | — | Europe | Class only |
| Annual incidence | <1 / 1 000 000 | 0.003 | Austria | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.004 | Belgium | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.003 | Croatia | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.001 | Czech Republic | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.001 | Germany | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.003 | Ireland | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.001 | Italy | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.005 | Latvia | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.003 | Spain | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.001 | Netherlands | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.002 | United Kingdom | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)